19:54 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

FDA lifts hold on Aptose blood cancer candidate

Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) said FDA lifted a two-and-a-half year clinical hold on a Phase Ib trial evaluating IV APTO-253 in patients with hematologic malignancies. In 2015, FDA placed a hold on the open-label, dose-escalation,...
21:28 , May 24, 2018 |  BC Extra  |  Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over the...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
17:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

APTO-253: Development delayed

Aptose said it will “temporarily delay clinical activities” for its IV APTO-253 to allow the company to investigate the cause of manufacturing issues. Aptose said it will prioritize its resources on preclinical cancer candidate CG026806...
07:00 , Oct 27, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction Mouse studies suggest transiently promoting KLF9 expression could help treat age-related memory impairment. In aged and middle-aged mice, transient overexpression of KLF9 in the dentate gyrus increased contextual memory compared with normal KLF9...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

Aptose said it received a response from FDA regarding a clinical hold the agency placed last November on its open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. According to Aptose,...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

Aptose said it submitted a formal response to FDA’s requests following a November 2015 clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The company had voluntarily...
07:00 , Apr 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK); kruppel-like factor 2 (KLF2); kruppel-like factor 4 (KLF4; EZF)

Cardiovascular disease INDICATION: Cardiovascular Patient sample and mouse studies suggest inhibiting the MAP4K3-KLF2/KLF4 pathway could help treat cerebral cavernous malformations (CCMs), which involve the formation of highly dilated blood vessels and symptoms including headaches, seizures and hemorrhages....
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

FDA placed a clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The hold follows a voluntary suspension of dosing and preliminary review that found concerns regarding...
07:00 , Jul 30, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Kruppel-like factor 4 (KLF4; EZF); galectin-3 (LGALS3)

Cardiovascular disease INDICATION: Atherosclerosis Cell culture and mouse studies suggest inhibiting KLF4 could help treat atherosclerosis. In atherosclerotic plaques, phenotypic conversion of smooth muscle cells to macrophage-like LGALS3-positive cells increases inflammation and reduces fibrous cap area, which...